Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Research group performs randomized study to evaluate efficacy of ICCBco in treatment of lung lesions

To evaluate efficacy of Calculus Bovis compound preparation (ICCBco) in the treatment of lung lesions in portal hypertensive rabbits with schistosomiasis as the experimental animal model, a research group in China performed a randomized, double-blind, controlled trial to observe pathological changes and pathological effect mechanism of expression of fibronectin and laminin in the lung tissue of portal hypertensive rabbits with schistosomiasis.

6 Mar 2010

Increased risk of colorectal cancer associated with obesity may be restricted to tumors that have no MSI

The increased risk of colorectal cancer associated with obesity may be largely restricted to tumors that have no or low microsatellite instability (MSI), a common condition in most colorectal cancers, according to a new study published online March 8 in the Journal of the National Cancer Institute.

6 Mar 2010

US Oncology honored with FORTUNE magazine's World's Most Admired Companies distinction

US Oncology, Inc., the leading oncology services company uniting the nation's largest cancer treatment and research network to expand patient access to high-quality, cost-effective cancer care and advance the science of cancer care, has been named to FORTUNE magazine's World's Most Admired Companies list for 2010.

6 Mar 2010

Research Roundup: Childhood obesity, insurance coverage in cancer trials, hospitals stays and need for nursing homes

Health Affairs this month is devoted to the topic of childhood obesity, with the first study of the group - National, State, And Local Disparities In Childhood Obesity - pointing out that "new data from the 2007 National Survey of Children's Health show that the percentage of children ages 10-17 who are overweight ... remained stable, while the national prevalence of obesity (BMI in the ninety-fifth percentile and higher) grew significantly, from 14.8 percent in 2003 to 16.4 percent in 2007.

6 Mar 2010

Postoperative complications more likely to occur at low-volume institutions

The frequency of post-operative complications following surgery for liver cancer is associated with a hospital having a low volume of liver surgery. Investigators at The Cancer Institute of New Jersey (CINJ) are presenting that finding at the 63rd Annual Society of Surgical Oncology Symposium taking place this week in St. Louis. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

6 Mar 2010

Inpatient integrative medicine program can have significant impact on pain: Study

Non-traditional therapies relieve pain among a wide range of hospitalized patients as much as 50 percent, according to a first-of-a-kind study in the Journal of Patient Safety.

6 Mar 2010

Poniard Pharmaceuticals' picoplatin Phase 2 study in metastatic CRPC: Positive results

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced the presentation of positive final data, including survival data, from the Company's Phase 2 clinical trial of picoplatin as a first-line therapy in men with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC). The results were presented in a General Poster Session today at the 2010 American Society of Clinical Oncology's Genitourinary Cancers Symposium in San Francisco, CA.

6 Mar 2010

Saladax Biomedical announces closing of $8.4M Series C Preferred offering

Saladax Biomedical, Inc. announced today the close of an $8.4 million Series C Preferred offering led by Excel Venture Management of Boston. Participants included Golden Seeds LLC, Ben Franklin Technology Partners, and the Life Sciences Greenhouse of Central Pennsylvania, as well as a number of angel investors. The funding will be used to accelerate product development and expand clinical support of Saladax’s MYCARE™ line of diagnostic tests, which measure blood levels of cancer and Central Nervous System (CNS) disorder drugs, providing physicians with guidance to personalize patient dosing for optimal efficacy.

5 Mar 2010

Life Technologies, TGen, US Oncology collaborate to sequence genomes of triple negative breast cancer patients

Life Technologies Corporation today announced that it is collaborating with the Translational Genomics Research Institute and US Oncology to sequence the genomes of 14 patients afflicted with triple negative breast cancer whose tumors have progressed despite multiple other therapies.

5 Mar 2010

Predictive Biosciences to present its novel MADR approach during 2010 GU Symposium

Predictive Biosciences today announced that the Company will be presenting its novel Multi-Analyte Diagnostic Readout approach to the development of a non-invasive, urinary biomarker based assay for the detection of bladder cancer during the 2010 Genitourinary Cancers Symposium, being held March 5-7 in San Francisco.

5 Mar 2010

bioTheranostics launches CancerTYPE ID database and KRAS mutational testing

bioTheranostics, a bioMerieux company that discovers, develops and commercializes innovative molecular diagnostic tests in oncology, announces the launch of an expanded tumor-type database for its flagship product, CancerTYPE ID®, and the launch of KRAS mutational testing.

5 Mar 2010

Data evaluating safety, efficacy of STELARA and REMICADE in patients with plaque psoriasis to be presented

Data evaluating the efficacy and safety of STELARA™ (ustekinumab) and REMICADE® (infliximab) in patients with plaque psoriasis who had an inadequate response to Enbrel® (etanercept) will be presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) in Miami, Fla., from March 5-9, 2010.

5 Mar 2010

Leading experts to discuss latest pharmacogenomic research at European Lung Cancer Conference

Rapid advances in drug development, genetics and multidisciplinary treatment have brought the field of oncology to a critical moment, says Dr. Rafael Rosell from the Catalan Institute of Oncology in Badalona, Spain, co-chair of the second European Lung Cancer Conference (ELCC), which will be held in Geneva, Switzerland from 28 April to 1 May 2010.

4 Mar 2010

Acupuncture may reduce joint pain and stiffness caused by routine breast cancer therapy

A new study, led by researchers at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center, demonstrates that acupuncture may be an effective therapy for joint pain and stiffness in breast cancer patients who are being treated with commonly used hormonal therapies. Results were published in the Journal of Clinical Oncology.

4 Mar 2010

BioVex commences dosing in Phase 1 study of ImmunoVEX live attenuated genital herpes vaccine

BioVex Inc, a private biotechnology company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that the first subject had been dosed in the Phase 1 study of its live attenuated genital herpes vaccine, ImmunoVEXHSV2. The Phase 1 study is an open label ascending dose trial, assessing safety and immune response in healthy volunteers. The study is taking place in the UK at the Chelsea and Westminster Hospital in London and will involve up to 42 already identified subjects.

4 Mar 2010

Testimony emphasizes that health reform bills eliminate prostate cancer screening

The House Committee on Oversight and Government Reform, chaired by Congressman Edolphus Towns, will hold a hearing entitled: "Prostate Cancer: New Questions About Screening and Treatment."

4 Mar 2010

Celldex Therapeutics reports net loss of $13.5M for fourth-quarter of 2009

Celldex Therapeutics, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. Celldex reported a net loss of $13.5 million, or $0.43 per share, for the fourth quarter of 2009 compared to a net loss of $7.5 million, or $0.47 per share, for the fourth quarter of 2008.

4 Mar 2010

Diplomat Specialty Pharmacy to help patients obtain financial assistance to purchase life-saving drugs

Diplomat Specialty Pharmacy, the nation's largest privately held specialty pharmacy company, is on a mission to help patients obtain the financial assistance they need to purchase life-saving drugs for such illnesses as cancer, HIV/AIDS and Hepatitis C, as well as drugs for Multiple Sclerosis, kidney disease and other chronic conditions.

4 Mar 2010

SpePharm Holding acquires global rights to Savene from TopoTarget

SpePharm Holding, BV today announced the acquisition of the worldwide (with the exception of North and South America) rights to Savene® from TopoTarget A/S (Copenhagen, Denmark). As part of the acquisition SpePharm will also take on the European sales force of TopoTarget. Savene®, which has been marketed by TopoTarget since its approval by the EMEA in July 2006, is the only approved product for the treatment of extravasations, or leakage out of the blood stream, of certain commonly used anticancer drugs known as anthracyclines.

4 Mar 2010

Arc radiotherapy treatments: Breakthrough in image-guided targeting of prostate tumors

Researchers in the US and Denmark have made a breakthrough in image-guided targeting of prostate tumors during arc radiotherapy treatments. In research partially supported by Varian Medical Systems, physicists at Stanford University (California, USA) and Aarhus University Hospital (Aarhus, Denmark) have devised a method for 'real-time' tracking of the prostate motion using Varian's On-Board Imager® that shows promise in paving the way for advanced clinical treatments.

4 Mar 2010

Oncology News and Research

Further Reading

Research group performs randomized study to evaluate efficacy of ICCBco in treatment of lung lesions

Increased risk of colorectal cancer associated with obesity may be restricted to tumors that have no MSI

US Oncology honored with FORTUNE magazine's World's Most Admired Companies distinction

Research Roundup: Childhood obesity, insurance coverage in cancer trials, hospitals stays and need for nursing homes

Postoperative complications more likely to occur at low-volume institutions

Inpatient integrative medicine program can have significant impact on pain: Study

Poniard Pharmaceuticals' picoplatin Phase 2 study in metastatic CRPC: Positive results

Saladax Biomedical announces closing of $8.4M Series C Preferred offering

Life Technologies, TGen, US Oncology collaborate to sequence genomes of triple negative breast cancer patients

Predictive Biosciences to present its novel MADR approach during 2010 GU Symposium

bioTheranostics launches CancerTYPE ID database and KRAS mutational testing

Data evaluating safety, efficacy of STELARA and REMICADE in patients with plaque psoriasis to be presented

Leading experts to discuss latest pharmacogenomic research at European Lung Cancer Conference

Acupuncture may reduce joint pain and stiffness caused by routine breast cancer therapy

BioVex commences dosing in Phase 1 study of ImmunoVEX live attenuated genital herpes vaccine

Testimony emphasizes that health reform bills eliminate prostate cancer screening

Celldex Therapeutics reports net loss of $13.5M for fourth-quarter of 2009

Diplomat Specialty Pharmacy to help patients obtain financial assistance to purchase life-saving drugs

SpePharm Holding acquires global rights to Savene from TopoTarget

Arc radiotherapy treatments: Breakthrough in image-guided targeting of prostate tumors

Cancer Research eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News